易慕峰是一家致力于突破实体瘤治疗，给患者带来长期生存获益的免疫细胞治疗药物开发企业。
Location: China
Investors 1
| Date | Name | Website |
| 26.10.2023 | triwise | en.triwise... |
Mentions in press and media 4
| Date | Title | Description |
| 13.01.2026 | Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ | SHANGHAI, Jan. 13, 2026 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based anti-C... |
| 05.09.2025 | Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy | SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. T... |
| 02.06.2024 | Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting | CHICAGO, June 2, 2024 /PRNewswire/ -- On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for ... |
| 23.02.2024 | Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors | - The first EpCAM targeted CAR-T product obtained US/CN IND approval. - Acceptable safety profiles and preliminary efficacy were observed in Investigator-Initiated Trial (IIT) clinical studies of IMC001. SHANGHAI, Feb. 23, 2024 /PRNewswire/... |